


CLEMEX intelligent microscopy

Measure what you see.
See what you measure.



Q2 2007-2008


For the quarter ended October 31st, 2007

Table of Contents

2	. MD&A
10	. Q2 Financial Statements
13	. Notes to Consolidated Financial Statements
17	. Corporate Information

The accompanying unaudited interim consolidated financial statements have been prepared by management of Clemex Technologies Inc. and have not been reviewed by the external auditors of the Company. They must be read in parallel with the annual financial statements prepared by the Company on April 30, 2007.

The financial statements include some amounts and assumptions based on management's estimates which have been derived with best judgement. These assumptions are subject to a certain number of risks and uncertainties that could make the actual events and results be different than originally anticipated.



" The Clemex PSA300 is an exceptionally powerful instrument, and the relationship with Horiba Instruments will greatly improve the product's market penetration."

Clément Forget
President and CEO

Management Discussion and Analysis

For the quarter ending October 31st, 2007

This discussion and analysis is provided to assist readers in their assessment and understanding of the consolidated results of operations, the financial position and changes in cash flows of Clemex Technologies Inc. for the second quarter ending October 31st, 2007.

Description of Business

Clemex Technologies, Inc. ("Clemex" or "the Company") develops, manufactures and markets image analysis systems and software used by quality control and research microscopy laboratories. Clemex's customer base spans over many countries around the world and encompasses large manufacturing concerns in numerous industries including automotive, aerospace, raw materials manufacturing, pharmaceuticals, mining, and other sectors.

Clemex Technologies' headquarter is located in Longueuil, QC, and has a business office in the US, as well as distributors in Europe, Asia, South America, and the Middle East. The Company is publicly traded on the Alberta stock exchange under the symbol "CXG.A".

Analysis of Financial Position and Results of Operations

Consolidated Statement of Operations for the three and six month period ending October 31st, 2007.

	Three months ended October 31st		Six months ended October 31st		Notes
	2008	2007	2008	2007	
	\$	\$	\$	\$	
Sales	1,502,403	1,398,350	2,607,677	2,682,848	1
Cost of sales	602,276	566,534	992,943	1,115,173	2
Gross profit	900,127	831,816	1,614,734	1,567,675	
Operating expenses:					
Sales & Marketing expenses	418,440	412,715	819,443	777,336	3
Administrative expenses	288,060	191,645	505,111	352,561	4
R&D expenses, net of tax credit	135,404	122,302	270,088	254,363	5
Depreciation	25,719	18,547	51,439	42,388	6
Interest & bank charges	33,107	30,609	64,171	58,184	7
Foreign exchange loss	65,935	15,824	109,799	18,603	7
	966,665	791,642	1,820,051	1,503,435	
Net earnings	(66,538)	40,174	(205,317)	64,240	8

During this second Quarter of FY2008, income reached \$1,502 M compared to \$1,398 M for the same period last year. After six months, income reached \$2,607 in 2008 compared to \$2,682 in 2007. The gross margin was of 59.9% for this period whereas it was of 59.4% last year. The cumulative margin has risen to 61.9% in 2008, compared to 58.4% in 2007.

The spectacular rise of the Canadian dollar, and the non-recurring expenses incurred during the Annual General Meeting, affected our finances substantially and the net result was a quarter weaker than anticipated with a slight deficit of \$66,538. After six months in this fiscal year, the Company has accumulated a deficit of \$205,317.

Consolidated Balance Sheet

	As of October 31st 2007 (unaudited)	As of April 30th 2007 (audited)	Notes
Assets			
	\$	\$	
Current assets:			
Cash and cash equivalents	-	70,802	9
Accounts receivable	1,277,040	997,878	10
Tax credits receivable	373,735	249,288	11
Inventories	653,485	601,547	12
Prepaid expenses	43,096	38,244	
	2,347,356	1,957,759	
Capital assets	337,340	399,427	
Long-term assets held for disposal	9,637	9,637	
Deferred financing costs net of accumulated amortization of \$40,882 (2006 : \$26,021)	17,542	3,717	
	2,711,875	2,370,540	
Liabilities and Shareholders' Equity			
Current liabilities:			
Bank overdraft	32,070	-	
Bank indebtedness	495,352	225,000	
Bank demand loans	234,318	-	13
Accounts payable & accrued liabilities	839,897	746,601	14
Customer deposits & deferred revenue	1,781	19,403	
Current portion of long-term debt	37,017	130,975	
	1,640,435	1,121,979	
Long-term debt	67,705	78,197	15
Convertible debenture	223,949	214,874	
Shareholders' Equity:			
Other component of shareholders' equity (note 2)	84,312	84,312	
Capital stock	4,216,890	4,203,950	16
Contributed surplus	87,376	70,703	
Deficit	(3,608,792)	(3,403,475)	
	779,786	955,490	
	2,711,875	2,370,540	

References to the Summary of Consolidated Results and Balance Sheet.

1. Sales.

An increase of \$104,053 for this quarter. A cumulative decrease of \$75,271.

Sales for this last quarter have increased compared to the same period last year.

Although the first two quarters are usually weaker in terms of income, mainly due to summer vacations, this sales increase bears witness to the efforts made during these last months to build up the order book. In addition, had it not been for the strength of the Canadian dollar these last few months, sales would have been higher as retail prices could not be readjusted for bids already tendered to customers on such short notice.

2. Cost of sales.

Stable at 59.9 % for this quarter.

The cost of sales includes supplies and human resources costs associated with filling our orders. It also includes labour, packaging, manuals, and delivery costs, as well as expenditures associated with the set-up of products at our clients' place of business.

The types of product sold, having different characteristics and requiring different preparations and installation, is mostly responsible for cost variations from one quarter to the next.

3. Sales and marketing.

An increase of \$5,725 for this quarter, a cumulative of \$42,107.

Sales and marketing expenses include marketing and sales personnel wages, commissions, travel expenses, trade shows, and advertising.

Marketing expenses are nearly the same as last year. There were no extraordinary activities or important changes in the sales and marketing team during the last quarter. The trade shows attended in the first quarter are responsible for the year to date increase in expenses.

4. Administrative expenses.

An increase of \$96,415 for this quarter, a cumulative of \$152,550.

General and administrative expenses consist primarily of costs relating to management, human resources, finance, as well as rent and other office expenses, professional fees and other general overhead expenses.

The increase in administrative expenses for this last quarter is due to the extraordinary rise of professional fees nearing \$73,000 linked to the Annual General Meeting and the cost of provision linked with the granting of options. Other administrative expenditures were similar to the same period last year.

5. Research and development expenses.

An increase of \$13,102 for this quarter, a cumulative of \$15,725.

Research and development expenses include personnel and consultant costs required to develop and support the products development of the Company.

The slight increase in R&D expenses for this past quarter is due to external professional service expenditures incurred for the development of new products, which will soon be marketed. The Company has not recruited new R&D staff during this quarter, nor since the beginning of the fiscal year.

6. Depreciation.

An increase of \$7,172 for this quarter, a cumulative of \$9,051.

Depreciation expenditures are higher compared to the previous year. They take into account expenses for equipment purchased during the last fiscal year that are amortized according to their respective categories and the applicable rates granted to each of them.

7. Financial expenses.

Interest & bank charges, increase of \$2,498 and 5,987 cumulative. Foreign currency lost, increase of \$50,111 and 91,196 cumulative.

Financial expenses consist of interest on term loans, bank charges and foreign currency gains and losses. During the last quarter, the following financial expenses were incurred.

	3 months	6 months
	\$	\$
Interest and bank charges	25,462	41,862
Interest on the long-term debt	7,645	22,309
Losses on foreign Currency transactions	65,935	109,799
	99,042	173,970

The Company suffered a loss of more than \$65,935 this last quarter linked to currency fluctuations. The cumulative loss is established at \$109,799 from the beginning of the fiscal year. The strength of the Canadian dollar is responsible for the most part of the operational deficit accumulated during the last six months of operation.

8. Net earnings.

A decrease of \$106,712 for this quarter, a cumulative of \$269,557.

The Company achieved lower net earnings this last quarter due to expenses linked with the extraordinary Annual General Assembly and to the very strong resurgence of the Canadian dollar. Other expenditures respect the budget drawn up at the beginning of the fiscal year, and had it not been for these two factors, the Company would certainly have succeeded in ending its last quarter on a positive note.

9. Cash and cash equivalents.

A decrease of \$152,487.

The cash inflow for the last quarter was;

Operating activities	(110,384)
Financing activities	226,265
Investing activities	4,536
Net cash inflow (outflow)	120,417

The Company's short-term working capital was affected by the losses of the last two quarters. Consequently, the Company started financing of its research and development appropriation in order to free the credit margin and use it for current operations. As of October 31st, the treasury and working capital ratios are of 1.43 and 1.03 respectively.

Management, aware of the present short term cash assets difficulties is looking at various avenues to use its under-exploited borrowing power to maximize the financial lever available.

10. Accounts receivable.

An increase of \$279,162.

The average recovery ratio of the accounts receivable is basically the same, and ranges between 45 and 60 days, depending on customer terms of payment. No bad credit was recorded during the second quarter. The increase in sales for this last quarter explains the increase in accounts receivable as of October 31st, 2007.

11. Tax credits receivable.

An increase of \$124,447.

The tax credits on investment are the Quebec government refundable R&D.

The amount shown in the current assets represents the current investment net of R&D tax credits.

12. Inventories.

An increase of \$51,938.

Inventory represents the goods that the Company has on hand to prepare orders and to resell its finished products to its customers.

Inventories are primarily made up of microscope components, cameras, motorized stages, and computers.

13. Accounts payable.

An increase of \$93,296.

Accounts payable represent accrued and incurred liabilities as of October 31st, 2007, such as supplier accounts for a total of \$622,006, and other expenses such as wages, vacations, commissions, taxes, and professional fees for a total of \$217,891.

The variability is mainly due to a timing difference in the payment of bi-weekly payrolls and of supplier accounts which are paid on a 45-day cycle.

14. Bank indebtedness and bank demand loans

The corporation has at its disposal a revolving operating line of credit of \$ 500,000. This credit bears interest at bank prime rate plus 1.25% and is secured by a first bank moveable mortgage of \$ 1,275,000 on the universality of the inventories, accounts receivables, and assets.

The Corporation also has bank demand loans of \$ 376,000, at prime rate plus 1.75 %, pledged by a moveable hypothec on the refundable tax credits receivable, maturing in February 2008 and February 2009. Investissement Quebec guaranties these loans up to 80%.

15. Total long term debt.

A decrease of \$104,405.

Details of debt are as follows:

	October 31st 2007	April 30th 2007
\$750,000 debt due in October 2007, guaranteed by Investissement Québec with monthly payments of \$15,625, carrying interest at the basic rate plus 2%	15,625	109,375
\$107,000 term debt due in October 2011, carrying interest at the basic rate plus 2.5%, with monthly payment of capital of \$1,782.65	89,097	99,797
Total	104,722	209,172
Short-term portion	37,017	130,975
Long-term debt	67,705	78,197
Convertible debentures	223,949	214,874

The Company must maintain a debt ratio under 2.0. This ratio is 1.86 as of October 31st, 2007.

The Company had issued, in 2005, a debenture of \$500,000 at a rate of 9%, maturing in August 2008. The Company can force conversion of the principle amount at the above mentioned conversion rate, on the condition that the average share exchange is maintained at \$0.70 for a period of 20 consecutive days.

16. Share Capital

The issued common share capital is as follows:

	On December 15th 2007	On October 31st 2007	On April 30th 2007
Options issued and outstanding	1,098,000	1,098,000	858,000
Shares issued and outstanding	18,743,810	18,732,810	18,740,268

The Company has the authorization from the TSX Venture Exchange to repurchase shares in the normal course of activities since December 12th, 2006. A total of 936,500 class "A" shares can be repurchased and cancelled during the next 12 months. During the second quarter of 2008, the Company did not repurchase nor cancel any common shares.

Selected Quarterly Financial Information

	2008			2007			2006	
	Q2	Q1	Q4	Q3	Q2	Q1	Q4	Q3
	\$	\$	\$	\$		\$	\$	\$
Revenue	1,502,403	1,105,274	1,197,982	1,463,992	1,398,350	1,284,497	1,543,244	1,564,570
Earnings/ net losses 1	(66,538)	(138,780)	(202,645)	79,159	40,174	24,066	42,620	172,303
BPA	(0.004)	(0.007)	(0.011)	0.004	0.002	0.001	0.002	0.010
BPA (diluted)	(0.004)	(0.007)	(0.011)	0.004	0.002	0.001	0.002	0.010
Earnings/ Net losses 2	(66,538)	(138,780)	(202,645)	79,159	40,174	24,066	40,564	172,303
BPA	(0.004)	(0.007)	(0.011)	0.004	0.002	0.001	0.002	0.010
BPA	(0.004)	(0.007)	(0.011)	0.004	0.002	0.001	0.002	0.010

Note 1) Net earnings or (net losses) from continuing activities, basic per share and diluted per share.

Note 2) Net earnings or (net losses) including discontinued activities, basic per share and diluted per share.

Risks and Uncertainties

Protection in the form of patents is generally not available for software products such as those produced by the Company. There can be no assurance that the Company's means of protecting its proprietary rights will be adequate or that the Company's competitors will not independently develop similar technology. However the Company does take whatever steps it can to protect itself.

Additional risks and uncertainties which are not presently known could adversely affect the Company, such as changes in economic or political environment, dependence on a particular industry, changes in foreign exchange rates, fluctuations in sales cycles and demand for products, as well as the ability to attract and retain key personnel.

Subsequent Events

On November 7th, 2007, the Company signed an exclusivity agreement concerning the distribution of its newly developed Clemex PS3 instrument with Horiba Instruments Inc of Irvine California. This agreement will allow Clemex to combine its image analysis expertise with the marketing power of Horiba and penetrate the particle sizing market much more efficiently.

Disclosure Controls and Procedures

As of October 31st, 2007, there were no changes to the design of disclosure controls and procedures and to the design of internal controls over financial reporting.

This Management Discussion and Analysis report was prepared on December 15th, 2007. For more information, please visit the SEDAR website at: www.sedar.com.



CLEMEX intelligent microscopy

Financial Statements Q2 2007-2008

Consolidated Balance Sheet

As of October 31, 2007 with comparative figures of April 30, 2007

	October 31st 2007 (unaudited) \$	April 30th 2007 (audited) \$
Assets		
Current assets:		
Cash and cash equivalents	-	70,802
Accounts receivable	1,277,040	997,878
Research & development tax credit receivable	373,735	249,288
Inventories	653,485	601,547
Prepaid expenses	43,096	38,244
	2,347,356	1,957,759
Capital assets (note 3)	337,340	399,427
Long-term assets held for disposal	9,637	9,637
Deffered financing costs net of accumulated amortization of \$ 40 882 (2006: \$ 26 021)	17,542	3,717
	2,711,875	2,370,540
Liabilities and shareholder's equity		
Current Liabilities		
Bank Overdraft	32,070	-
Bank indebtedness (note 4)	495,352	225,000
Bank demand loans (note 4)	234,318	-
Accounts payable & accrued liabilities (note 5)	839,897	746,601
Customers deposits & deferred revenue	1,781	19,403
Current portion of long-term debt (note 6)	37,017	130,975
	1,640,435	1,121,979
Long-term debt (note 6)	67,705	78,197
Convertible debenture	223,949	214,874
Shareholders' equity:		
Other component of shareholders' equity	84,312	84,312
Share capital (note 9)	4,216,890	4,203,950
Contributed surplus	87,376	70,703
Deficit	(3,608,792)	(3,403,475)
	779,786	955,490
	2,711,875	2,370,540

See accompanying notes to consolidated financial statements

Consolidated Interim Income Statement

For the three month and six month period ending October 31, 2007 (unaudited)

	Second Quarter		Six Months	
	2007-08	2006-07	2007-08	2006-07
	\$	\$	\$	\$
Sales	1,502,403	1,398,350	2,607,677	2,682,848
Cost of sales	602,276	566,534	992,943	1,115,173
Gross profit	900,127	831,816	1,614,734	1,567,675
Operating Expenses				
Sales & Marketing expenses	418,440	412,715	819,443	777,336
Administrative expenses	288,060	191,645	505,111	352,561
Research and development, net of tax credits	135,404	122,302	270,088	254,363
Depreciation	25,719	18,547	51,439	42,388
Interest & bank charges	33,107	30,609	64,171	58,184
Foreign exchange loss	65,935	15,824	109,799	18,603
	966,665	791,642	1,820,051	1,503,435
Net earnings before	(66,538)	40,174	(205,317)	64,240
Deficit, beginning	(3,542,254)	(3,320,163)	(3,403,475)	(3,344,229)
Deficit, end	(3,608,792)	(3,279,989)	(3,608,792)	(3,279,989)
Net earnings (loss) per share				
Basic	(0.004)	0.002	(0.011)	0.003
Diluted	(0.004)	0.002	(0.011)	0.003
Weighted average number of shares outstanding	18,732,810	18,793,060	18,732,810	18,793,060
Dilutive effect of stock options (1)	-	-	-	-
Diluted weighted average number of shares	18,732,810	18,793,060	18,732,810	18,793,060

See accompanying notes to consolidated financial statements

(1) The effect of dilutive effect of stock options and the convertible debenture are not included as the effect would be anti-dilutive

Consolidated Cash Flow Statement

For the three month and six month period ending October 31, 2007 (unaudited)

	Second Quarter		Six Months	
	2007-08	2006-07	2007-08	2006-07
	\$	\$	\$	\$
Operating Activities				
Earning from continuing operations	(66,538)	40,174	(205,317)	64,241
Adjustment for:				
Depreciation	25,719	18,547	51,439	42,388
Amortization of deferred financing costs	5,367	1,859	7,226	3,718
Increase in the value of the convertible debenture	4,538	3,040	9,076	5,875
Loss (Gain) on disposal of capital assets	-	-	-	-
	(30,914)	63,620	(137,576)	116,222
Net change in non-cash working capital items	(79,470)	(225,589)	(384,725)	(359,721)
Cash provided by (used for) continuing operating activities	(110,384)	(161,969)	(522,301)	(243,499)
Financing Activities				
Bank indebtedness	25,000	275,000	270,352	175,000
Deferred Financing	-	-	(21,050)	-
Financing of the R&D income tax credits	234,318	-	234,318	-
Issuing of shares (category A)	12,040	7,700	12,940	7,700
Other components of shareholders' equity	7,132	-	16,672	-
Repayment of long-term debt	(52,225)	(48,461)	(104,450)	(96,893)
Cash provided by (used for) continuing financing activities	226,265	234,239	408,782	89,410
Investing activities				
Acquisition of capital assets	(8,829)	(26,965)	(14,689)	(48,571)
Proceeds from disposal of capital assets	13,365	57	25,336	57
Cash provided by continuing investing activities	4,536	(26,908)	10,647	(48,514)
Net loss (net increase) in cash and cash equivalents of continuing operations	120,417	45,362	(102,872)	(206,207)
CASH, BEGINNING	(152,487)	(33,614)	70,802	217,955
CASH, END	(32,070)	11,748	(32,070)	11,748

Notes to consolidated interim financial statements

For the second quarter ending October 31, 2007

1. Basis of presentation

Description of activities

Clemex Technologies Inc. develops, manufactures and markets image analysis systems and software used by quality control and research microscopy laboratories.

Basis of presentation

These consolidated financial statements have been prepared in conformity with Canadian generally accepted principles. The same accounting policies as described in the latest annual report have been used. However, these consolidated financial statements do not include all disclosures required under generally accepted accounting principles and accordingly should be read in connection with the consolidated financial statements and the notes thereto included in the Corporation's latest Annual report.

Seasonability of interim period operations

The first two trimesters ending July 31 and October 31 are traditionally slower months in terms of sales due to summer break period . Nevertheless, given the long sales cycles, the Company's results can fluctuate from quarter to quarter.

2. Accounting Policies

These interim unaudited consolidated financial statements have been prepared in accordance with Canadian generally accounting principles with respect to the preparation of interim statements. Therefore, these statements do not include all the information normally presented with regards to annual financial statements and must be read along with annual financial statements prepared on April 30th, 2007. The income statements for the interim periods presented do not necessarily represent the anticipated year end results for this current fiscal year.

3. Capital Assets

	Cost	Accumulated Amortization	Net Book Value
	\$	\$	\$
To October 31 2007 (unaudited)			
Equipment	284,330	235,244	49,086
Moving Laboratory	214,184	100,793	113,391
Research and Development equipment	648,466	570,362	78,104
Computer equipment	184,443	122,301	62,142
Furniture and fixtures	211,861	177,244	34,617
	1,543,284	1,205,944	337,340

3. Capital Assets (cont'd)

	Cost	Accumulated Amortization	Net Book Value
	\$	\$	\$
To April 30 2007 (audited)			
Equipment	253,855	202,283	51,572
Moving Laboratory	214,184	90,092	124,092
Research and Development equipment	694,046	577,894	116,152
Computer equipment	204,847	135,712	69,135
Furniture and fixtures	211,861	173,385	38,476
	1,578,793	1,179,366	399,427

4. Bank indebtedness and bank demand loans

The Corporation has at its disposal a revolving operating line of credit of \$ 500,000. This credit bears interest at bank prime rate plus 1.25 % and is secured by a first bank moveable mortgage of \$ 1,275,000 on the universality of the Corporation's goods.

The Corporation also has bank demand loans of \$ 376,000, at prime rate plus 1.75 %, pledged by a moveable hypothec on the refundable tax credits, maturing in February 2008 and February 2009. Investissement Québec guarantees these loans up to 80 %.

14

5. Accounts payable and accrued liabilities

	Unaudited to October 31 2007	Audited to April 30 2007
Suppliers	622,006	442,043
Accrued Liabilities	166,154	187,413
Salaries and fringe benefits	51,737	117,145
	839,897	746,601

6. Long Term Debt

	Unaudited to October 31 2007	Audited to April 30 2007
Term loan, bearing interest at prime rate plus 2.5 %, payable by monthly instalments of \$ 15,625 plus interest due in November 2007, secured by a collateral loan of 80 % by Investissement Québec	15,625	109,375
Instalment loan, bearing interest at prime rate plus 2.5 %, payable by monthly instalments of \$ 1,782 plus interest, due in October 2011, secured by equipment with a net book value of \$ 124,091.	89,097	99,797
	104,722	209,172
Current portion of long-term debt	37,017	130,975
Long term debt	67,705	78,197

7. Stock option plan

As per the stock option plan, the Corporation may grant options from time to time to its employees and directors. Options granted under the plan may be exercised over a period of 5 years from the date they were granted and expire no later than the anniversary date.

Variations in stock-option outstanding and the effect on the weighted average exercise price are summarized as follows:

		Number of options	Weighted average exercise price
Balance, as of April 30th, 2007		858,000	0.20
Options granted	first quarter	10,000	
	second quarter	478,000	
Options exercised	first quarter	5,000	
	second quarter	63,000	
Options cancelled	first quarter	100,000	
	second quarter	80,000	
Balance as of October 31, 2007		1,098,000	0.20

Under the stock option plan terms, the options granted can be exercised at different dates. Therefore, of the total options granted, 80 000 were exercisable immediately, 199 000 after a six month period and 199 000 after twelve months.

An amount of \$ 7 132 was accounted for during this quarter as a result of options granted.

8. Segmented information

The sales are broken in geographic area as follows. The sales attributed to each geographic are based on the location of the customer.

Quarter ending October 31, 2007

	2nd trimester	Unaudited FY 2008 6 months	2nd trimester	Audited FY 2007 6 months
Sales				
Canada	419,811	733,549	352,054	666,650
United States	737,795	1,334,801	875,914	1,476,859
Other countries	344,797	539,327	170,382	539,339
	1,502,403	2,607,677	1,398,350	2,682,848

9 Capital

The issued and outstanding common type "A" share capital of the Corporation is as follows:

	Nbr. shares
Balance as of April 30 2007	18,669,810
Shares issued with respect to options granted	63,000
Repurchased shares (1)	-
Balance as of October 31, 2007	18,732,810
Shares issued with respect to options granted	11,000
Repurchased shares (1)	-
Balance as of December 15, 2007	18,743,810

(1) *The Corporation has obtained authorization to proceed to the purchase of a maximum of 5 % of its outstanding shares of the public float on December 12, 2006 through the Normal Course Issuer Bid. No shares were purchased and cancelled during the first quarter, from May 1st to July 31, 2007.*

Corporate Information

Headquarters

Clemex Technologies Inc.
800 Guimond, Longueuil, Quebec
J4G 1T5 Canada
Telephone: (450) 651-6573
Fax: (450) 651-9304
info@clemex.com
www.clemex.com

Subsidiary

Clemex Corp
17195 Silver Parkway, suite 409
Fenton, MI USA
48430-3426

Transfer Agent

CIBC Mellon Trust
Montreal, Quebec

Auditors

Raymond Chabot
Grant Thornton S.E.N.C.R.L.
Chartered Accountants
Longueuil, Quebec

Solicitors

Ogilvy Renault
Montreal, Quebec

Bankers

National Bank of Canada
Montreal, Quebec

Trading Symbol

Trading Symbol Clemex Technologies Inc.
is listed on The Canadian Venture Exchange
(CDNX) under the symbol CXG.A

Authorized Number of Class A Shares

unlimited

Issued Class A Shares

18,743,810

December 15th, 2007

Board of Directors

Me Lisane Dostie

*Chairperson of the Board and
Corporate Secretary,
Recruiter
Fitzwilliam Legal Recruitment*

Normand Beauregard

*Director,
Marketing Consultant and UQAM Professor*

Gilles L'Espérance, PhD

*Director,
Material Engineering, Associate Professor
École Polytechnique*

Clément Forget

*Director,
President and Chief Executive Officer
Clemex Technologies Inc.*

Eric Grandjean

*Director,
President
Compumedia Design*

Frédéric Tremblay

*Director,
Vice-President
HKDP (Hill & Knowlton)*

Officers

Clément Forget

*President and Chief Executive Officer
Clemex Technologies Inc.*

Caroline Trudel

*Treasurer,
Vice-President, Finances & Administration
Clemex Technologies Inc.*

Monique Dallaire, eng.

*Vice-President,
Marketing and Product Development
Clemex Technologies Inc.*

www.clemex.com



A small gesture for the environment. When you finish reading this report, you can give it to another person or put it in the recycling bin. You can also consult our financial statements on line at www.clemex.com or at www.sedar.com.